Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

D. P. Petrylak, R. Macarthur, J. O'Connor, G. Shelton, A. Weitzman, T. Judge, C. England-Owen, N. Zuech, C. Pfaff, J. Newhouse, E. Bagiella, D. Hetjan, I. Sawczuk, M. Benson, C. Olsson

Research output: Contribution to journalReview article

86 Citations (Scopus)

Abstract

Evaluation of the combined regimen of estramustine and docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) in men with hormone- refractory prostate cancer is in its early stages. While this combination is promising in terms of efficacy, adverse events associated with estramustine are a concern. Estramustine has been associated with side effects such as nausea, vomiting, edema, and serious vascular events. Reported here are the results of phase I and phase II trials in which 280 mg estramustine was given three times daily on days I to 5 in 21-day treatment cycles with docetaxel at varying doses. Data from patients evaluable thus far support the efficacy of this combination, both in chemotherapeutically naive patients and in those who have had prior therapy. A survival benefit from this combination appears achievable from these early studies. As significant antitumor activity can be achieved with docetaxel alone, future studies need to define the minimal dose of estramustine for this combination.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalSeminars in Oncology
Volume26
Issue number5 SUPPL. 17
StatePublished - Dec 1 1999

Fingerprint

docetaxel
Estramustine
Prostatic Neoplasms
Hormones
Nausea
Vomiting
Blood Vessels
Edema
Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Petrylak, D. P., Macarthur, R., O'Connor, J., Shelton, G., Weitzman, A., Judge, T., ... Olsson, C. (1999). Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Seminars in Oncology, 26(5 SUPPL. 17), 28-33.

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. / Petrylak, D. P.; Macarthur, R.; O'Connor, J.; Shelton, G.; Weitzman, A.; Judge, T.; England-Owen, C.; Zuech, N.; Pfaff, C.; Newhouse, J.; Bagiella, E.; Hetjan, D.; Sawczuk, I.; Benson, M.; Olsson, C.

In: Seminars in Oncology, Vol. 26, No. 5 SUPPL. 17, 01.12.1999, p. 28-33.

Research output: Contribution to journalReview article

Petrylak, DP, Macarthur, R, O'Connor, J, Shelton, G, Weitzman, A, Judge, T, England-Owen, C, Zuech, N, Pfaff, C, Newhouse, J, Bagiella, E, Hetjan, D, Sawczuk, I, Benson, M & Olsson, C 1999, 'Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer', Seminars in Oncology, vol. 26, no. 5 SUPPL. 17, pp. 28-33.
Petrylak DP, Macarthur R, O'Connor J, Shelton G, Weitzman A, Judge T et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Seminars in Oncology. 1999 Dec 1;26(5 SUPPL. 17):28-33.
Petrylak, D. P. ; Macarthur, R. ; O'Connor, J. ; Shelton, G. ; Weitzman, A. ; Judge, T. ; England-Owen, C. ; Zuech, N. ; Pfaff, C. ; Newhouse, J. ; Bagiella, E. ; Hetjan, D. ; Sawczuk, I. ; Benson, M. ; Olsson, C. / Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. In: Seminars in Oncology. 1999 ; Vol. 26, No. 5 SUPPL. 17. pp. 28-33.
@article{847defa5d64e481bb57974e3adb0bcda,
title = "Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer",
abstract = "Evaluation of the combined regimen of estramustine and docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) in men with hormone- refractory prostate cancer is in its early stages. While this combination is promising in terms of efficacy, adverse events associated with estramustine are a concern. Estramustine has been associated with side effects such as nausea, vomiting, edema, and serious vascular events. Reported here are the results of phase I and phase II trials in which 280 mg estramustine was given three times daily on days I to 5 in 21-day treatment cycles with docetaxel at varying doses. Data from patients evaluable thus far support the efficacy of this combination, both in chemotherapeutically naive patients and in those who have had prior therapy. A survival benefit from this combination appears achievable from these early studies. As significant antitumor activity can be achieved with docetaxel alone, future studies need to define the minimal dose of estramustine for this combination.",
author = "Petrylak, {D. P.} and R. Macarthur and J. O'Connor and G. Shelton and A. Weitzman and T. Judge and C. England-Owen and N. Zuech and C. Pfaff and J. Newhouse and E. Bagiella and D. Hetjan and I. Sawczuk and M. Benson and C. Olsson",
year = "1999",
month = "12",
day = "1",
language = "English (US)",
volume = "26",
pages = "28--33",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 17",

}

TY - JOUR

T1 - Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

AU - Petrylak, D. P.

AU - Macarthur, R.

AU - O'Connor, J.

AU - Shelton, G.

AU - Weitzman, A.

AU - Judge, T.

AU - England-Owen, C.

AU - Zuech, N.

AU - Pfaff, C.

AU - Newhouse, J.

AU - Bagiella, E.

AU - Hetjan, D.

AU - Sawczuk, I.

AU - Benson, M.

AU - Olsson, C.

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Evaluation of the combined regimen of estramustine and docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) in men with hormone- refractory prostate cancer is in its early stages. While this combination is promising in terms of efficacy, adverse events associated with estramustine are a concern. Estramustine has been associated with side effects such as nausea, vomiting, edema, and serious vascular events. Reported here are the results of phase I and phase II trials in which 280 mg estramustine was given three times daily on days I to 5 in 21-day treatment cycles with docetaxel at varying doses. Data from patients evaluable thus far support the efficacy of this combination, both in chemotherapeutically naive patients and in those who have had prior therapy. A survival benefit from this combination appears achievable from these early studies. As significant antitumor activity can be achieved with docetaxel alone, future studies need to define the minimal dose of estramustine for this combination.

AB - Evaluation of the combined regimen of estramustine and docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) in men with hormone- refractory prostate cancer is in its early stages. While this combination is promising in terms of efficacy, adverse events associated with estramustine are a concern. Estramustine has been associated with side effects such as nausea, vomiting, edema, and serious vascular events. Reported here are the results of phase I and phase II trials in which 280 mg estramustine was given three times daily on days I to 5 in 21-day treatment cycles with docetaxel at varying doses. Data from patients evaluable thus far support the efficacy of this combination, both in chemotherapeutically naive patients and in those who have had prior therapy. A survival benefit from this combination appears achievable from these early studies. As significant antitumor activity can be achieved with docetaxel alone, future studies need to define the minimal dose of estramustine for this combination.

UR - http://www.scopus.com/inward/record.url?scp=0033406879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033406879&partnerID=8YFLogxK

M3 - Review article

C2 - 10604266

AN - SCOPUS:0033406879

VL - 26

SP - 28

EP - 33

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 17

ER -